Abstract: Alkynyl-derivatized cap analogs, alkynyl-modified capped RNA, 1,4-disubstituted triazole-derivatized capped RNA, methods of preparation, methods of isolation, and uses thereof are provided. The “click” modification facilitates detection and isolation of capped RNAs and the 1,4-disubstituted triazole derivatives formed by the “click” reaction are useful for producing RNA transcripts and encoded protein.
Type:
Grant
Filed:
October 18, 2012
Date of Patent:
March 3, 2015
Assignee:
Life Technologies Corporation
Inventors:
Anilkumar R. Kore, Shanmugasundaram Muthian, Kyle Gee
Abstract: Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.
Type:
Application
Filed:
January 11, 2010
Publication date:
March 1, 2012
Inventors:
Stanley Chamberlain, Jeff Hutchins, Karolina Madela, Christopher McGuigam, John Vernachio, Mohamed Aljarah, Arnaud Gilles
Abstract: The antimelancholic medicine or health products prepared with jujuba cAMP materials and the preparative method are provided in the present invention.
Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (?)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
December 23, 2008
Assignee:
Emory University
Inventors:
Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
Abstract: The invention concerns a method for binding nucleic acids to a solid phase in which a nucleic acid containing solution is contacted with a solid phase which has hydrophobic and hydrophilic groups on its surface or/and which comprises a hydrophilic, water-containing polymer matrix, in the presence of dehydrating reagents, in particular in the presence of a salt and polyethylene glycol whereby the nucleic acid is bound to the surface.
Type:
Grant
Filed:
September 8, 2000
Date of Patent:
April 4, 2006
Assignee:
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften. E.V.
Inventors:
Holger Rauth, Richard Reinhardt, Eckard Nordhoff
Abstract: Propargylethoxyamino nucleosides are disclosed having the structure wherein R1 and R2 are —H, lower alkyl, or label; B is a 7-deazapurine, purine, or pyrimidine nucleoside base; W1 is —H or —OH; W2 is —OH or a moiety which renders the nucleoside incapable of forming a phosphodiester bond at the 3?-position; and W3 is —PO4, —P2O7, —P3O10, phosphate analog, or —OH. Additionaly, a primer extension method is provided employing the above propargylethoxyamino nucleosides.
Type:
Grant
Filed:
July 9, 2002
Date of Patent:
March 28, 2006
Assignee:
Applera Corporation
Inventors:
Shaheer H. Khan, Steven M. Menchen, Barnett B. Rosenblum
Abstract: A method for efficiently purifying 5′ protected 2′-deoxypurine nucleosides, efficient production of which has previously been difficult. Impurities can be separated by obtaining the 5′ protected 2′-deoxypurine nucleoside as an inclusion crystal including a solvent such as that having a nitrile structure in order to purify the 5′ protected 2′-deoxypurine nucleoside at a high purity. This invention enables synthesis of highly purified protected deoxypurine nucleosides easily on a large scale, which has previously been performed by column chromatography method.
Abstract: A compound of formula (I) wherein B1 is a radical of a nucleoside base, R1 is hydrogen or a hydroxy-protecting group, R2 is hydrogen, hydroxy or a 2′-nucleoside-modifying atom or group, R3 is an unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl, C4 to C10 cycloalkylalkyl, C6 to C10 aryl or C7 to C13 aralkyl group, and Z is halogen or a group of formula (II) where R4 and R5 are each independently an unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl, C4 to C10 cycloalkylalkyl, C6 to C10 aryl or C7 to C13 aralkyl group, or R4 is said group and R5 is hydrogen or R4 and R5 together with the nitrogen atom to which they are attached denote a five- to thirteen-membered heterocyclic ring, or Z is a group of formula (III): Nuc-O—, where Nuc is the residue of a natural or synthetic nucleoside or oligonucleotide after removal of a 5′-hydroxyl group therefrom attached through a 5′-methylene thereof to the indicated oxygen atom.
Type:
Grant
Filed:
March 15, 1999
Date of Patent:
December 11, 2001
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Stephen Paul Collingwood, Heinz Ernst Moser, Karl-Heinz Altmann, Mark Edward Douglas
Abstract: A method for the stepwise creation of phosphodiester bonds between desired nucleosides resulting in the synthesis of polynucleotides having a predetermined nucleotide sequence by preparing an initiation substrate containing a free and unmodified 3′-hydroxyl group; attaching a mononucleotide selected according to the order of the predetermined nucleotide sequence to the 3′-hydroxyl of the initiating substrate in a solution containing a catalytic amount of an enzyme capable of catalyzing the 5′ to 3′ phosphodiester linkage of the 5′-phosphate of the mononucleotide to the 3′-hydroxyl of the initiating substrate, wherein the mononucleotide contains a protected 3′-hydroxyl group, whereby the protected mononucleotide is covalently linked to the initiating substrate and further additions are hindered by the 3′-hydroxyl protecting group. Methods in which a mononucleotide immobilized on a solid support is added to a free polynucleotide chain are also disclosed.